ReviewEvidence-based complementary and alternative medicine : eCAM2018
Efficacy of Suxiao Jiuxin Pill on Coronary Heart Disease: A Meta-Analysis of Randomized Controlled Trials.
Review in Evidence-based complementary and alternative medicine : eCAM, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Suxiao Jiuxin Pill Promotes Post-Myocardial Infarction Cardiac Repair by Enhancing Regulatory T Cell Function via the ST2L Signaling Pathway.Journal of inflammation research · 2026Article
- Genome-wide identification and characterization of the AP2/ERF gene family in Cinnamomum camphora.BMC genomics · 2025Article
- Unpredictable Chemical Diversity of Essential Oils inMolecules (Basel, Switzerland) · 2024Article
- Suxiao Jiuxin Pill attenuates acute myocardial ischemia via regulation of coronary artery tone.Frontiers in pharmacology · 2023Article
- Exosomes: A novel insight into traditional Chinese medicine.Frontiers in pharmacology · 2022Review
- Traditional Chinese Medicine "Pill", an Ancient Dosage Form with Surprising Modern Pharmaceutical Characteristics.Pharmaceutical research · 2021Review
- Genome-Wide Identification and Functional Characterization of the Trans-Isopentenyl Diphosphate Synthases Gene Family inFrontiers in plant science · 2021Article
- Salvia miltiorrhiza improves Alzheimer's disease: A protocol for systematic review and meta-analysis.Medicine · 2020Article
- Fenofibrate-induced hepatotoxicity: A case with a special feature that is different from those in the LiverTox database.Journal of clinical pharmacy and therapeutics · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Suxiao jiuxin pill is considered an effective ancillary drug in patients with coronary heart disease. Although numerous small, single-center clinical trials have been conducted, the benefits and harms of suxiao jiuxin pill remain controversial. We performed a meta-analysis to clarify the efficacy of suxiao jiuxin pill on patients with coronary heart disease. Randomized controlled trials were identified by using the Cochrane Library, PubMed, Web of Science, Embase, Wanfang, Weipu, and China Knowledge Resource Integrated databases (until June 2016). Pooled relative risks (RR), weighted mean differences (WMD), and 95% confidence intervals (95% CIs) were estimated using random-effects models. Forty-one trials involving 6276 patients were included in our analysis. Administration of suxiao jiuxin pill significantly improved electrocardiogram (ECG) results when compared with other therapies (RR 1.32, 95% CI 1.26 to 1.38, and
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.